Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
23 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Covagen AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Covagen AG - Product Pipeline Review - 2014', provides an overview of the Covagen AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Covagen AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Covagen AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Covagen AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Covagen AG's pipeline products Reasons to buy - Evaluate Covagen AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Covagen AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Covagen AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Covagen AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Covagen AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Covagen AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Covagen AG Snapshot 4 Covagen AG Overview 4 Key Information 4 Key Facts 4 Covagen AG - Research and Development Overview 5 Key Therapeutic Areas 5 Covagen AG - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Out-Licensed Products 9 Out-Licensed Products/Combination Treatment Modalities 10 Covagen AG - Pipeline Products Glance 11 Covagen AG - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Covagen AG - Early Stage Pipeline Products 12 Discovery Products/Combination Treatment Modalities 12 Covagen AG - Drug Profiles 13 COVA-322 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 COVA-208 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 FynomAb-1 for Oncology 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 FynomAb-2 for Oncology 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Covagen AG - Pipeline Analysis 17 Covagen AG - Pipeline Products by Target 17 Covagen AG - Pipeline Products by Molecule Type 18 Covagen AG - Pipeline Products by Mechanism of Action 19 Covagen AG - Recent Pipeline Updates 20 Covagen AG - Locations And Subsidiaries 21 Head Office 21 Appendix 22 Methodology 22 Coverage 22 Secondary Research 22 Primary Research 22 Expert Panel Validation 22 Contact Us 23 Disclaimer 23
List of Tables Covagen AG, Key Information 4 Covagen AG, Key Facts 4 Covagen AG - Pipeline by Indication, 2014 6 Covagen AG - Pipeline by Stage of Development, 2014 7 Covagen AG - Monotherapy Products in Pipeline, 2014 8 Covagen AG - Out-Licensed Products in Pipeline, 2014 9 Covagen AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 10 Covagen AG - Phase I, 2014 11 Covagen AG - Discovery, 2014 12 Covagen AG - Pipeline by Target, 2014 17 Covagen AG - Pipeline by Molecule Type, 2014 18 Covagen AG - Pipeline Products by Mechanism of Action, 2014 19 Covagen AG - Recent Pipeline Updates, 2014 20
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.